Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients

Pedersen, 1998, Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study, Circulation, 97, 1453, 10.1161/01.CIR.97.15.1453

Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, N. Engl. J. Med., 335, 1001, 10.1056/NEJM199610033351401

1998, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels, N. Engl. J. Med., 339, 1349, 10.1056/NEJM199811053391902

Shepherd, 1995, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia, N. Eng. J. Med., 333, 1301, 10.1056/NEJM199511163332001

Downs, 1998, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS, JAMA, 279, 1615, 10.1001/jama.279.20.1615

Thompson, 1997, What targets should lipid-modulating therapy achieve to optimize the prevention of coronary heart disease?, Atheriosclerosis, 131, 1, 10.1016/S0021-9150(97)06084-X

Gould, 1998, Cholesterol reduction yields clinical benefit: impact of statin trials, Circulation, 97, 946, 10.1161/01.CIR.97.10.946

Miller, 1975, Plasma high density lipoprotein concentration and development of ischemic heart disease, Lancet, i, 16, 10.1016/S0140-6736(75)92376-4

Gordon, 1989, High density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies, Circulation, 79, 8, 10.1161/01.CIR.79.1.8

Hokanson, 1996, Plasma triglyceride level is a risk factor for cardiovascular disease independent of high density lipoprotein cholesterol level: a meta-analysis of population-based studies, J. Cardiovasc. Risk, 3, 213, 10.1097/00043798-199604000-00014

Krauss, 1998, Triglycerides and atherogenic lipoproteins: rationale for lipid management, Am. J. Med., 105, 48S, 10.1016/S0002-9343(98)00213-7

Goldbourt, 1997, Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men, Arterioscler. Thromb. Vasc. Biol., 17, 107, 10.1161/01.ATV.17.1.107

Eckardstein, 2000, Prevention of coronary heart disease by raising high-density lipoprotein cholesterol, Curr. Opin. Lipidol., 11, 627, 10.1097/00041433-200012000-00010

Castelli, 1988, Cholesterol and lipids in the risk of comnary artery disease: the Framingham Heart Study, Can. J. Cardiol., 8, 207

Assmann, 1996, High density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport, Atherosclerosis, 124, S11, 10.1016/0021-9150(96)05852-2

Asztalos, 2000, Distribution of apoA-I-containing HDL subpopulations in patients with coronary heart disease, Arterioscler. Thromb. Vasc. Biol., 20, 2670, 10.1161/01.ATV.20.12.2670

Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ. Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients, Journal of Lipid Research, in press.

McNamara, 1987, Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions, Clin. Chim. Acta, 166, 1, 10.1016/0009-8981(87)90188-4

Warnick, 1982, Dextran sulfate-Mg procedure for quantitation of high density lipoprotein cholesterol, Clin. Chem., 28, 1379, 10.1093/clinchem/28.6.1379

Nguyen, 1989, Improved methods for separation of total HDL and subclasses, Clin. Chem., 35, 1086

McNamara, 1995, Immunoseparation method for measuring low-density lipoprotein cholesterol directly from serum evaluated, Clin. Chem., 41, 232, 10.1093/clinchem/41.2.232

Contois, 1996, Reference intervals for plasma apolipoprotein A-I determined with a standardized commercial immunoturbidometric assay: results from the Framingham Offspring Study, Clin. Chem., 42, 515, 10.1093/clinchem/42.4.515

Asztalos, 1993, Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations, Biochim. Biophys. Acta, 1169, 291, 10.1016/0005-2760(93)90253-6

Asztalos, 1997, Normolipidemic subjects with low HDL cholesterol levels have altered HDL subpopulations, Arterioscler. Thromb. Vasc. Biol., 17, 1885, 10.1161/01.ATV.17.10.1885

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 2001; 285: 2486–2497.

Jones, 1998, Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia. (The Curves Study), Am. J. Cardiol., 81, 582, 10.1016/S0002-9149(97)00965-X

Branchi, 1999, Lowering effects of four different statins on serum triglyceride level, Eur. J. Clin. Pharmacol., 55, 499, 10.1007/s002280050663

Davidson M, McKinney J, Stein E, Schrott H, Bakker-Arkema R, Fayyad R et al. for the Atorvastatin Study Group I. Comparison of the one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol 1997; 79: 1475.

Bertolini, 1997, Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia, Atherosclerosis, 130, 191, 10.1016/S0021-9150(96)06052-2

Dart A, Jerums G, Nicholson G, et al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997; 80: 39–44.

Fruchart, 1992, Apolipoprotein A-containing lipoprotein particles: physiological role, quantification, and clinical significance, Clin. Chem., 38, 793, 10.1093/clinchem/38.6.793

Cheung, 1991, Altered partical size distribution of apolipoprotein A-I containing lipoproteins in subjects with coronary heart disease, J. Lipid Res., 32, 383, 10.1016/S0022-2275(20)42061-9

von Eckardstein, 1994, Physiological role and clinical relevance of high density lipoprotein subclasses, Curr. Opin. Lipidol., 5, 404, 10.1097/00041433-199412000-00003

Guerin, 2000, Action of atorvastatin in combined hyperlipidemia: referential reduction of cholesterol ester transfer from HDL to VLDL1 particles, Arterioscler. Thromb. Vasc. Biol., 20, 189, 10.1161/01.ATV.20.1.189

O'Neill, 2001, Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia, Arterioscler. Thromb. Vasc. Biol., 21, 832, 10.1161/01.ATV.21.5.832